SOURCE: DNAPrint Genomics, Inc.

November 16, 2006 17:44 ET

DNAPrint Genomics Recommends Federal Source for Funding of DNA "Cold Case" Tests

SARASOTA, FL -- (MARKET WIRE) -- November 16, 2006 -- DNAPrint Genomics, Inc. (OTCBB: DNAG) today announced that, in order to encourage the use of DNA testing in the solving of so-called "cold cases," the National Institute of Justice (NIJ), through its DNA grant program, provides funding to assist in the investigative and analysis process.

In 2005, the National Institute of Justice (NIJ) provided $14 million in funding to 38 States and units of local government to search, evaluate, select, and conduct DNA analysis on violent crime "cold cases" that have the potential to be solved through DNA testing, according to federal government sources.

NIJ also provides funding to support regional training opportunities for "cold case" investigators from law enforcement agencies nationwide. These training events are being delivered by NIJ through its cooperative agreement with the National Forensic Technology Center, a member of the NIJ Forensic Resource Network, according to federal government sources.

To receive notification of grant opportunities as they become available, register at

Other resources for the "cold case" investigator are available on the NIJ website,

"After returning from several law enforcement agency conventions, including the International Association of Chiefs of Police in Boston last month, our sales and marketing department learned of the genuine interest in the Company's DNAWitness™ and Retinome™2.0 products," stated DNAPrint President and Chief Executive Officer Richard Gabriel. "We also learned that there may be federal funds available to reimburse some or all of the costs of DNA testing that could be used to solve cold cases. We thought it would be prudent to share this information with all law enforcement officials and the public at large, and to encourage law enforcement agencies at all levels to pursue this source of funding."

DNAWitness™ employs patent-pending, database-driven methods to infer elements of physical appearance from crime scene DNA and allow forensic investigators to "paint" molecular portraits of a suspect. Retinome™2.0 can be combined with the DNAWitness™ product to determine a person's eye color. The Company's patent-pending technology identifies additional markers covering newly identified and informative regions of the human pigmentation gene OCA2.

About DNAPrint Genomics, Inc.

DNAPrint Genomics, Inc. ( is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company's proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company's first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (with end stage renal disease). Preclinical and clinical development of all the Company's drug candidates will benefit from simulated pre-trials to design actual trials better and are targeted to patients with genetic profiles indicating their propensity to have the best clinical responses. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to for information on law enforcement and consumer applications which include DNAWITNESS™, RETINOME™, ANCESTRYbyDNA™ and EURO-DNA™. DNAWitness-Y and DNAWitness-Mito are two tests offered by the Company. The results from these tests may be used as identification tools when a DNA sample is deteriorated or compromised or other DNA testing fails to yield acceptable results.

Forward-Looking Statements

All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint Genomics, Inc. expressly disclaims any obligation or undertaking, except as may be required by applicable law or regulation to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.

Contact Information

  • Company Contact:
    Richard Gabriel
    CEO and President
    941 366-3400
    Ron Stabiner
    The Wall Street Group, Inc.